Analysts See Big Upside For Newly Listed Molecular Diagnostic Firm BillionToOne After Standout IPO Rally

Benzinga2025-12-02

BillionToOne, Inc., (NASDAQ:BLLN) recently completed an upsized initial public offering, or IPO, of 5.23 million shares at $60 each, raising roughly $314 million. The company, a commercial-stage ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588447772?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/01/Other-Key-Trades.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2025-12-02 01:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588447772","market":"hk","top_or_hot":-1,"title":"Analysts See Big Upside For Newly Listed Molecular Diagnostic Firm BillionToOne After Standout IPO Rally","media":"Benzinga","content":"<div>\n<p>BillionToOne, Inc., (NASDAQ:BLLN) recently completed an upsized initial public offering, or IPO, of 5.23 million shares at $60 each, raising roughly $314 million. \nThe company, a commercial-stage ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49142994/analysts-see-big-upside-for-newly-listed-molecular-diagnostic-firm-billiontoone\">Source Link</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Analysts See Big Upside For Newly Listed Molecular Diagnostic Firm BillionToOne After Standout IPO Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnalysts See Big Upside For Newly Listed Molecular Diagnostic Firm BillionToOne After Standout IPO Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-02 01:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49142994/analysts-see-big-upside-for-newly-listed-molecular-diagnostic-firm-billiontoone><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BillionToOne, Inc., (NASDAQ:BLLN) recently completed an upsized initial public offering, or IPO, of 5.23 million shares at $60 each, raising roughly $314 million. \nThe company, a commercial-stage ...</p>\n\n<a href=\"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49142994/analysts-see-big-upside-for-newly-listed-molecular-diagnostic-firm-billiontoone\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49142994/analysts-see-big-upside-for-newly-listed-molecular-diagnostic-firm-billiontoone","article_id":"2588447772","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/01/Other-Key-Trades.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49142994/analysts-see-big-upside-for-newly-listed-molecular-diagnostic-firm-billiontoone","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2588447772","pubTimestamp":1764611580,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Analysts launch bullish coverage on BillionToOne as its IPO surge, prenatal growth, and molecular diagnostics platform drive optimism.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","BLLN":"BillionToOne, Inc."},"translate_title":"分析师认为新上市的分子诊断公司BillionToOne在IPO强劲反弹后有巨大上涨空间","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLLN":1.5},"content_text":"BillionToOne, Inc., (NASDAQ:BLLN) recently completed an upsized initial public offering, or IPO, of 5.23 million shares at $60 each, raising roughly $314 million. \nThe company, a commercial-stage molecular diagnostics company, offers specialized tests in prenatal genetics and oncology.\nIts patented Quantitative Counting Templates (QCT) platform uses multiplex technology to count DNA molecules at the single-molecule level.\n“There is strong appetite for high-growth, profitable diagnostic companies, and we believe this should continue given the sector's macro backdrop,” William Blair’s Andrew Brackmann wrote in a research note. “We have confidence that BillionToOne can deliver at, or more likely above, our estimates.”\nIn addition to William Blair’s Outperform rating, several other firms initiated coverage as well:\nBillionToOne's platform enables highly precise molecular diagnostics, bolstering its position in prenatal and oncology testing and supporting margin growth. \nAnalysts note strong prenatal momentum, with the UNITY test offering comprehensive genetic screening from a single blood draw, positioning the company for meaningful gains in the $2.5 billion U.S. prenatal market. \nWilliam Blair’s Brackmann expects continued growth from expanded sales reach, greater test awareness, broader payer coverage, guideline updates, and future product launches.\nPrice Action: BLLN stock is down 11.94% at $114.63 at the last check on Monday.\nShares are up 113% since pricing its many-times-oversubscribed IPO (compared to the S&P 500 +0%) and now trade at 18 times 2026 revenue.\nRead Next:\nImage: Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588447772","isCrawlerRequest":true}